

The Effect of Long Non-coding RNA ZFAS1 Knockdown on microRNA Expression

in Colon Adenocarcinoma



Andre Rochet, B.A.^{1, 2}, Casey Fiechter, B.S.¹, Stephen O'Brien, MB BCh BAO¹, Susan Galandiuk, M.D.¹ ¹Price Institute of Surgical Research, Hiram C. Polk Jr. MD Department of Surgery, Louisville, KY ²University of Louisville School of Medicine, Louisville, KY


Introduction

- Stage III and IV colorectal cancer (CRC) are associated with poor prognosis and survival compared to earlier disease stages.
- Long non-coding RNAs (IncRNAs) have a role in regulating epithelial-to-mesenchymal transition (EMT) and tumor progression. IncRNAs have several mechanisms of action, one being a decoy for microRNA.
- ZFAS1 is a IncRNA that is upregulated in CRC and has been shown to interact with the miR-200 family.
- The miR-200 family represses EMT, and is associated with more favorable prognosis.
- We hypothesized that ZFAS1 knockdown would lead to an increase in the expression of the miR-200 family.
- Additionally, we studied if transfection with miR-200 family mimics would lead to decreased expression of ZFAS1.

Methods

- Two CRC cell lines (SW480 and HT29, Duke's B and Duke's C, respectively) were grown in culture medium until confluent.
- Cells were plated into separate wells at a concentration of 1.6x10⁵ cells/well, and allowed to adhere for 24 hrs.
- The cells were then transfected with a ZFAS1 silencing RNA (siRNA), along with miR-200b mimics, miR-200c mimics, or negative controls.
- RNA was extracted at 24, 48, and 72 hrs post-transfection.
- Reverse transcription and quantitative Real-Time Polymerase Chain Reaction were performed to determine the expression of miR-200b, miR-200c, and ZFAS1.

Results






Fig. 1: (A-F) Results are in comparison to respective non-targeting siRNA with a fold regulation normalized to 1. Fig. 1: (A) Following ZFAS1 siRNA transfection in CRC cells in the HT29 (Duke's C colon adenocarcinoma) cell line, both miR-200b and 200c showed increased expression at 24 hrs post-transfection (Fold change=2.35, p<0.001, and Fold change= 3.03, p<0.001, respectively). Fig. 1: (B) miR-200b and 200c expression was also significantly increased in the SW480 (Duke's B colon adenocarcinoma) cell line at 24 hrs post-transfection (Fold change= 8.17, p=0.01, and Fold change= 10.2, p=0.01, respectively).

1C) HT29 (Duke's C colon adenocarcinoma) ZFAS1 expression after miR200b mimic transfection Median ± Interquartile Range





Fig. 1: (C&D) Following transfection of miR-200b and 200c mimics in the HT29 cell line, ZFAS1 expression was significantly decreased at 24, 48, and 72 hrs (p<0.05) post-transfection. No significant fold change regulation was observed at 12 hrs posttransfection with miR-200b and 200c mimics in the HT29 cell line (p>0.05).

Results (continued)






Fig. 1 (E) Following transfection of miR-200b mimics in the SW480 cell line, ZFAS1 was significantly decreased at 48, and 72 hrs (p<0.05); however, no significant fold change regulation was observed at 12 or 24 hrs posttransfection (p>0.05). Fig. 1 (F) Following transfection of miR-200c mimics in the SW480 cell line, ZFAS1 was also significantly decreased at 48 hrs, however, no significant fold change regulation was observed at 12, 24, or 72 hrs post-transfection (p>0.05). P values were determined using an unpaired ttest and results were considered significant when p<0.05.

Conclusions

- As hypothesized, knockdown of ZFAS1 leads to an increase in the expression of the miR-200 family in both cell lines.
- Similarly, transfection with miR-200 family mimics leads to decreased expression of ZFAS1, as hypothesized.
- These findings suggest that ZFAS1 has a direct relationship with the miR-200 family.
- *ZFAS1 may facilitate tumor progression by inhibiting expression of the miRNA-200 family, therefore blocking the inhibition of EMT.
- ZFAS1 must be further investigated as a potential target in the treatment of CRC.

Acknowledgements

Research supported by a grant from the National Cancer Institute Grant R25-CA134283 and the John Willamson and Barbara Thruston Atwood Price Trust.